Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effects of MIND Diet on Brain Fog, Stress, and Sleep Quality in Young Adults (Young Mind)

19. november 2026 oppdatert av: Halic University

The Effect of a MIND Diet-Based Nutritional Intervention on Brain Fog, Perceived Stress, Sleep Quality, and Selected Biochemical Findings in Young Adults

This study aims to evaluate the effects of a MIND diet-based nutritional intervention on brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. It will also compare the effects of the MIND diet with those of the Mediterranean diet and usual dietary habits.

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) is a dietary pattern that combines elements of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets. It emphasizes the consumption of green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, poultry, and olive oil, while limiting foods high in saturated fat, processed foods, and sweets. The Mediterranean diet similarly emphasizes plant-based foods, olive oil, whole grains, legumes, vegetables, fruits, nuts, and fish.

Young adults aged 18-35 years who meet the study eligibility criteria will be included. Participants will be randomly assigned to one of three groups: a MIND diet intervention group, a Mediterranean diet intervention group, or a control group.

Participants in the MIND diet group will receive nutritional guidance and follow a MIND diet-based dietary plan for 12 weeks. Participants in the Mediterranean diet group will receive nutritional guidance and follow a Mediterranean diet-based dietary plan for the same period. Participants in the control group will continue their usual dietary habits without receiving a structured dietary intervention during the study period.

Assessments will be conducted at baseline and at the end of the 12-week intervention. These assessments will include brain fog, perceived stress, sleep quality, dietary intake, and anthropometric measurements. Brain fog, perceived stress, and sleep quality will be evaluated using standardized assessment questionnaires. Dietary intake and adherence to the assigned dietary patterns will also be monitored throughout the intervention.

Selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, liver enzymes, uric acid, urea, and creatinine, will be assessed through blood samples.

The study will investigate whether following the MIND or Mediterranean dietary pattern for 12 weeks is associated with changes in brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. The findings may contribute to a better understanding of the relationship between dietary patterns and cognitive, psychological, sleep-related, and metabolic health.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

### Detailed Description

The MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet is a dietary pattern developed by combining elements of the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet. It emphasizes foods that may support brain and metabolic health, including green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, and poultry, while limiting the consumption of foods high in saturated fat, processed foods, sweets, and fried foods.

The Mediterranean diet is characterized by a high intake of vegetables, fruits, legumes, whole grains, nuts, seeds, and olive oil, with regular consumption of fish and moderate consumption of other animal-based foods. Both dietary patterns emphasize minimally processed, nutrient-dense foods and a balanced dietary approach.

This study is designed as a 12-week, randomized, parallel-group, three-arm interventional trial involving young adults aged 18-35 years. The study will compare the effects of a MIND diet-based nutritional intervention and a Mediterranean diet-based nutritional intervention with a control group that will maintain its usual dietary habits.

Participants assigned to the MIND diet group will receive individualized nutritional counseling and a dietary plan based on MIND diet principles. The intervention will emphasize the regular consumption of green leafy vegetables, other vegetables, berries, nuts, legumes, whole grains, fish, and poultry, while encouraging the limitation of foods associated with lower adherence to the MIND dietary pattern.

Participants assigned to the Mediterranean diet group will receive individualized nutritional counseling and a dietary plan based on Mediterranean diet principles. The intervention will emphasize vegetables, fruits, legumes, whole grains, olive oil, nuts, seeds, and fish as important components of daily and weekly food consumption.

Dietary plans will be individualized according to participants' age, sex, physical activity level, and estimated energy requirements. Participants in both intervention groups will receive nutritional guidance throughout the 12-week study period. Dietary adherence and food consumption will be monitored at 15-day intervals using dietary records, including three-day food consumption records, and adherence assessments.

Participants in the control group will not receive a structured dietary intervention and will be asked to maintain their usual dietary habits during the study period.

Baseline assessments will be performed before the dietary interventions begin. At the end of the 12-week intervention, the assessments will be repeated to evaluate changes over time.

The primary areas of assessment include brain fog, perceived stress, and sleep quality. Brain fog will be assessed using the Brain Fog Scale, perceived stress using the Perceived Stress Scale (PSS-10), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).

Anthropometric and body composition measurements will also be obtained, including body weight, height, body mass index (BMI), and body composition assessed by bioelectrical impedance analysis.

Fasting blood samples will be collected to evaluate selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid, urea, and creatinine.

The study aims to determine whether a 12-week MIND diet-based or Mediterranean diet-based nutritional intervention is associated with changes in brain fog, perceived stress, sleep quality, anthropometric measurements, and selected biochemical parameters in young adults. Comparisons between the three study groups will be used to evaluate the potential effects of the dietary interventions.

Studietype

Intervensjonell

Registrering (Antatt)

42

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 35 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 18-35 years.
  • Willingness to participate in the study and provide written informed consent.
  • Ability and willingness to follow the assigned dietary intervention for 12 weeks.
  • Ability to complete dietary records and study questionnaires.

Exclusion Criteria:

  • Presence of chronic diseases requiring a specific medical nutrition therapy.
  • Pregnancy or breastfeeding.
  • Food allergies or intolerances that prevent adherence to the study diets.
  • Following a medically prescribed or restrictive diet.
  • Regular use of medications that may significantly affect the study outcomes.
  • Any condition that may interfere with participation in the study or adherence to the intervention.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Mind Diet Group

Participants will receive a 12-week dietary intervention based on the MIND diet.

Participants will receive a 12-week dietary intervention based on the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

Eksperimentell: Mediterranean Diet Group

Participants will receive a 12-week dietary intervention based on the Mediterranean diet.

Participants will receive a 12-week dietary intervention based on the Mediterranean diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

Ingen inngripen: Control Group

Participants will not receive a specific dietary intervention during the 12-week study period.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Brain Fog Scale Score
Tidsramme: 12 weeks

Brain fog will be assessed using the 23-item Brain Fog Scale. The total score ranges from 0 to 92. Higher scores indicate more severe brain fog symptoms and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Pittsburgh Sleep Quality Index Scores
Tidsramme: 12 weeks

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Perceived Stress Scores
Tidsramme: 12 weeks

Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10). The total score ranges from 0 to 40. Higher scores indicate higher levels of perceived stress and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Fasting Blood Glucose Levels
Tidsramme: 12 weeks

Fasting blood glucose levels will be measured using standard biochemical laboratory methods after overnight fasting. Changes in fasting blood glucose levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Total Cholesterol Levels
Tidsramme: 12 weeks

Serum total cholesterol levels will be measured using standard biochemical laboratory methods. Changes in total cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Low-Density Lipoprotein (LDL) Cholesterol Levels
Tidsramme: 12 weeks

Serum low-density lipoprotein (LDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in LDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in High-Density Lipoprotein (HDL) Cholesterol Levels
Tidsramme: 12 weeks

Serum high-density lipoprotein (HDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in HDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Triglyceride Levels
Tidsramme: 12 weeks

Serum triglyceride levels will be measured using standard biochemical laboratory methods. Changes in triglyceride levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Aspartate Aminotransferase (AST) Levels
Tidsramme: 12 weeks

Serum aspartate aminotransferase (AST) levels will be measured using standard biochemical laboratory methods. Changes in AST levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Alanine Aminotransferase (ALT) Levels
Tidsramme: 12 weeks

Serum alanine aminotransferase (ALT) levels will be measured using standard biochemical laboratory methods. Changes in ALT levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Uric Acid Levels
Tidsramme: 12 weeks

Serum uric acid levels will be measured using standard biochemical laboratory methods. Changes in serum uric acid levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Urea Levels
Tidsramme: 12 weeks

Serum urea levels will be measured using standard biochemical laboratory methods. Changes in serum urea levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Creatinine Levels
Tidsramme: 12 weeks

Serum creatinine levels will be measured using standard biochemical laboratory methods. Changes in serum creatinine levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Ahmet Murat Günal, PhD, Haliç University
  • Hovedetterforsker: Murat Baş, PhD, Acibadem University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. mars 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

6. november 2026

Først innsendt som oppfylte QC-kriteriene

19. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • g5wmafbp

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared with other researchers due to privacy and confidentiality considerations. Data will be used solely for the purposes of this study and will be handled in accordance with applicable data protection regulations.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .